Suppr超能文献

伴有门静脉癌栓的肝细胞癌肿瘤微环境中细胞代谢的异质性。

The heterogeneity of cellular metabolism in the tumour microenvironment of hepatocellular carcinoma with portal vein tumour thrombus.

作者信息

Zhang Xiu-Ping, Zou Wen-Bo, Li Zhen-Qi, Yu Ze-Tao, Yu Shao-Bo, Lin Zhao-Yi, Wu Fei-Fan, Liu Peng-Jiong, Hu Ming-Gen, Liu Rong, Gao Yu-Zhen

机构信息

Faculty of Hepato-Biliary-Pancreatic Surgery, The First Medical Center of Chinese People's Liberation Army (PLA) General Hospital, Medical School of Chinese PLA, Beijing, China.

Department of General Surgery, No.924 Hospital of PLA Joint Logistic Support Force, Guilin, China.

出版信息

Cell Prolif. 2025 Jan;58(1):e13738. doi: 10.1111/cpr.13738. Epub 2024 Aug 27.

Abstract

Given the growing interest in the metabolic heterogeneity of hepatocellular carcinoma (HCC) and portal vein tumour thrombus (PVTT). This study comprehensively analysed the metabolic heterogeneity of HCC, PVTT, and normal liver samples using multi-omics combinations. A single-cell RNA sequencing dataset encompassing six major cell types was obtained for integrated analysis. The optimal subtypes were identified using cluster stratification and validated using spatial transcriptomics and fluorescent multiplex immunohistochemistry. Then, a combined index based meta-cluster was calculated to verify its prognostic significance using multi-omics data from public cohorts. Our study first depicted the metabolic heterogeneity landscape of non-malignant cells in HCC and PVTT at multiomics levels. The optimal subtypes interpret the metabolic characteristics of PVTT formation and development. The combined index provided effective predictions of prognosis and immunotherapy responses. Patients with a higher combined index had a relatively poor prognosis (p <0.001). We also found metabolism of polyamines was a key metabolic pathway involved in conversion of metabolic heterogeneity in HCC and PVTT, and identified ODC1 was significantly higher expressed in PVTT compared to normal tissue (p =0.03). Our findings revealed both consistency and heterogeneity in the metabolism of non-malignant cells in HCC and PVTT. The risk stratification based on cancer-associated fibroblasts and myeloid cells conduce to predict prognosis and guide treatment. This offers new directions for understanding disease development and immunotherapy responses.

摘要

鉴于对肝细胞癌(HCC)和门静脉肿瘤血栓(PVTT)代谢异质性的兴趣日益增加。本研究使用多组学组合全面分析了HCC、PVTT和正常肝脏样本的代谢异质性。获得了一个包含六种主要细胞类型的单细胞RNA测序数据集用于综合分析。使用聚类分层识别最佳亚型,并使用空间转录组学和荧光多重免疫组化进行验证。然后,计算基于组合指数的元聚类,以使用来自公共队列的多组学数据验证其预后意义。我们的研究首次在多组学水平描绘了HCC和PVTT中非恶性细胞的代谢异质性景观。最佳亚型解释了PVTT形成和发展的代谢特征。组合指数为预后和免疫治疗反应提供了有效的预测。组合指数较高的患者预后相对较差(p<0.001)。我们还发现多胺代谢是参与HCC和PVTT代谢异质性转化的关键代谢途径,并确定与正常组织相比,ODC1在PVTT中显著高表达(p = 0.03)。我们的研究结果揭示了HCC和PVTT中非恶性细胞代谢的一致性和异质性。基于癌症相关成纤维细胞和髓样细胞的风险分层有助于预测预后和指导治疗。这为理解疾病发展和免疫治疗反应提供了新的方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a5ef/11693549/da2cf638dd19/CPR-58-e13738-g004.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验